Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

PEGASUS: liquid-biopsy-guided adjuvant therapy for stage III and high-risk stage II colon cancer

Phase 2 study that changes capecitabine, CAPOX, or FOLFIRI according to serial ctDNA after surgery for microsatellite-stable stage III or T4N0 stage II colon cancer. ClinicalTrials.gov lists the status as unknown.

IFOM ETS - The AIRC Institute of Molecular Oncology